hs-CRP: Pharmacologic Interventions

In this episode, Dr. Michael Garshick discusses the role of pharmacologic interventions in managing inflammation and high-sensitivity CRP (hs-CRP) in cardiovascular (CV) disease. Key topics include the involvement of inflammation in atherosclerosis and atherothrombosis, traditional targets such as dyslipidemia, hypertension, and antiplatelet therapy, and the complexity of targeting inflammation and the inflammasome signaling pathway. He also explores insights from the CANTOS trial on IL-1 beta inhibitors and their impact on CV events and the role of colchicine in reducing CV events and its safety profile. Watch now to learn about the latest advancements in pharmacologic strategies for reducing cardiovascular risk through inflammation management.